Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C grosses €23mm for PanGenetics

Executive Summary

PanGenetics BV (antibodies for cancer, autoimmune, and pain conditions) raised €23mm ($34mm) through its Series C round. Edmond de Rothschild Investment Partners led and was joined by Biogen Idec New Ventures and Fortis Private Equity along with existing investors Index Ventures, Forbion Capital Partners, and Credit Agricole Private Equity.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies